A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Clinical trial NCT04224493 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04224493
- Sponsor
- Epizyme, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-11
- Primary completion
- 2027-02-13
- Enrollment
- 599
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.